Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction

Kjeld Schmiegelow, MD, DrMedSci,*‡ Stine N. Nielsen, MD,* Thomas L. Frandsen, MD, PhD,* and Jacob Nersting, MSc, PhD*

Summary: The antileukemic mechanisms of 6-mercaptopurine (6MP) and methotrexate (MTX) maintenance therapy are poorly understood, but the benefits of several years of myelosuppressive maintenance therapy for acute lymphoblastic leukemia are well proven. Currently, there is no international consensus on drug dosing. Because of significant interindividual and intraindividual variations in drug disposition and pharmacodynamics, vigorous dose adjustments are needed to obtain a target degree of myelosuppression. As the normal white blood cell counts vary by patients’ ages and ethnicity, and also within age groups, identical white blood cell levels for 2 patients may not reflect the same treatment intensity. Measurements of intracellular levels of cytotoxic metabolites of 6MP and MTX can identify nonadherent patients, but therapeutic target levels remains to be established. A rise in serum aminotransferase levels during maintenance therapy is common and often related to high levels of methylated 6MP metabolites. However, except for episodes of hypoglycemia, serious liver dysfunction is rare, the risk of permanent liver damage is low, and aminotransferase levels usually normalize within a few weeks after discontinuation of therapy. 6MP and MTX dose increments should lead to either leukopenia or a rise in aminotransferases, and if neither is experienced, poor treatment adherence should be considered. The many genetic polymorphisms that determine 6MP and MTX disposition, efficacy, and toxicity have precluded implementation of pharmacogenomics into treatment, the sole exception being dramatic 6MP dose reductions in patients who are homozygous deficient for thiopurine methyltransferase, the enzyme that methylates 6MP and several of its metabolites. In conclusion, maintenance therapy is as important as the more intensive and toxic treatment during induction and consolidation therapy. 4–8

The folate analog methotrexate (MTX) and the thio-substituted purine analog 6-mercaptopurine (6MP) became pioneering anticancer agents more than half a century ago, when first Farber et al1 and then Burchenal2,3 demonstrated that such drugs can induce temporary remissions in childhood leukemia. Soon cure became the goal,4,5 and through a series of trials it was shown that the chance of long-term remission of childhood acute lymphoblastic leukemia (ALL) was significantly improved, when patients received several years of postremission maintenance therapy with daily 6MP and weekly MTX.4–8

Today, ALL protocols include an induction regimen with 3 or 4 antileukemic drugs followed by several months of consolidation therapy.9–15 Then oral 6MP/MTX maintenance therapy is given until 2 to 3 years from diagnosis, the longer duration being reserved for boys due to their inferior prognosis with shorter therapy.16–20 Despite its long history, the antileukemic mechanisms of maintenance therapy remain to be revealed. Recent studies of NT5C2 mutations in relapsed ALL clones emerging during maintenance therapy21,22 support a direct antileukemic effect of 6MP/MTX possibly by modulating antiangiogenesis.21,31,32

The many genetic polymorphisms that determine 6MP and MTX disposition, efficacy, and toxicity have precluded implementation of pharmacogenomics into treatment, the sole exception being dramatic 6MP dose reductions in patients who are homozygous deficient for thiopurine methyltransferase, the enzyme that methylates 6MP and several of its metabolites. In conclusion, maintenance therapy is as important as the more intensive and toxic treatment during induction and consolidation therapy.4–8

Received for publication April 10, 2014; accepted May 14, 2014.

From the *Department of Paediatrics and Adolescent Medicine, University Hospital Righospitalet; and ‡Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.

Supported by grants from the Danish Childhood Cancer Foundation and the Danish Cancer Society.

The authors declare no conflict of interest.

Reprints: Kjeld Schmiegelow, MD, DrMedSci, Department of Paediatrics and Adolescent Medicine, University Hospital Righospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark (e-mail: kschmiegelow@rzh.dk).

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Website, www.jpho-online.com.

Copyright © 2014 by Lippincott Williams & Wilkins. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

J Pediatr Hematol Oncol • Volume 36, Number 7, October 2014 www.jpho-online.com | 503

IS YEARS OF 6MP/MTX THERAPY NEEDED FOR ALL PATIENTS?

Maintenance therapy seems to be important for most ALL subsets, including T-cell ALL21 and other patients with hyperleukocytosis at diagnosis33, adolescents,34 and Down syndrome patients with ALL.35 Observational studies support that 6MP/MTX maintenance therapy is superior to other drug combinations,33 and that poor physician compliance or poor patient adherence significantly increase the risk of relapse.36–39 As intensification of induction and consolidation therapy have improved cure rates of ALL, currently being > 80%,9,15,40 the necessity of
several years of the less toxic maintenance therapy has been questioned. A systematic review of 42 randomized studies with 12,000 childhood ALL cases indicated that longer maintenance therapy gave a slightly (although statistically significantly) lower risk of relapse, but with no difference in survival due to a higher risk of death in remission. Furthermore, longer duration of maintenance therapy as well as higher 6MP/MTX drug doses have in 3 recent studies been associated with an increased risk of second malignancies, but so far the subset of patients at risk of developing second cancers has not been identified. Shortening ALL therapy from 24 to 18 months significantly reduces the probability of event-free survival (pEFS), and if all chemotherapy is truncated at 52 weeks from diagnosis, the pEFS may be as low as 60%, even for non-high-risk ALL patients.

The fact that some children with ALL are cured after only a few months of chemotherapy is not surprising, as monitoring of minimal residual disease (MRD) has shown that patients may have $<10^{-5}$ leukemic cells in the bone marrow already at the end of induction therapy. Unfortunately, no randomized studies of therapy duration have included MRD monitoring.

**DRUG DOSAGE**

Maintenance therapy of childhood ALL is a challenging exception to the golden standard of body size-based drug dosing in cancer chemotherapy. Currently, there is no international consensus on administration of maintenance therapy, and protocols reflect tradition rather than empirical evidence. In most of continental Europe the starting dose of oral 6MP is 50 mg/m²/d, whereas in the United Kingdom, the Nordic countries, and most of the United States it is 75 mg/m²/d. For MTX, the starting dose varies from 20 to 40 mg/m²/d given orally, or sometimes parenterally to secure medication adherence and increase systemic drug exposure, although this route of administration has not been shown to be more efficacious and may even be more neurotoxic. In contrast, escalating intravenous MTX doses without leucovorin rescue during interim maintenance therapy seems to provide a better pEFS than oral MTX. However, without reliable pharmacological endpoints it is difficult to determine differences in the pharmacokinetic and pharmacodynamic aspects of these approaches.

The importance of 6MP/MTX dose intensity was first demonstrated in the 1960s, when children randomized to receive maintenance therapy with 6MP (50 mg/m²/d), MTX (20 mg/m²/wk), vincristine, and cyclophosphamide had longer remission duration than patients who only received half doses of these drugs to reduce toxicity. Because of large interindividual variations in 6MP/MTX bioavailability and cellular pharmacokinetics, patients receiving identical doses per body surface area may experience very different systemic and intracellular drug exposures. The doses of 6MP and MTX doses are poorly related to their AUC, and drug doses are not significantly related to relapse rates in multivariate analyses. Accordingly, the recommended 6MP and MTX doses in ALL protocols should only be regarded as starting doses that are to be individually adjusted according to myelotoxicity (Fig. 1, and Supplemental Fig. 1, Supplemental Digital Content 1, http://links.lww.com/JPHO/A72). The average 6MP and MTX doses prescribed during maintenance therapy and adjusted by WBC vary widely (Figs. 1, 2). Importantly, patients tolerant to the starting doses of 6MP and MTX, but for whom maintenance therapy is not intensified, have a poorer outcome compared both with patients who receive reduced drug doses due to leukopenia and with those who are upward dose adjusted to obtain target myelosuppression. Furthermore, recurrent unwarranted treatment interruptions due to a rise in amino-transferases are also an adverse factor for risk of relapse. In a more recent study, the cumulative duration of treatment interruptions, likely to be primarily determined by bone marrow toxicity and infections, did not seem to be related to an increased relapse rate in multivariate Cox regression analysis.

**6MP AND MTX PHARMACOKINETICS AND PHARMACODYNAMICS**

**6MP**

The absorption of 6MP is rapid, and the elimination half-life is short (1 to 2 h). Even though small studies (somewhat surprisingly) have been able to associate plasma 6MP concentrations to relapse rates, such measurements cannot be used for 6MP dose adjustments, due to very large (up to 70-fold) interindividual and intra-individual variations in bioavailability. 6MP has 3 major metabolic pathways (Fig. 3). First, a substantial and highly varying fraction of 6MP is converted to inactive 6-thiouric acid by the enzyme xanthine oxidase in first pass metabolism. Xanthine oxidase and thiorpurine methyltransferase (TPMT) can be inhibited by allopurinol, and coadministration of allopurinol thus requires 6MP dose reductions, as these interactions increase 6MP bioavailability and skew the metabolism of 6MP toward 6-thioguanine nucleotide (6TGN) production (Fig. 3). However, for childhood ALL this drug combination has not been explored beyond case reports.

Second, 6MP is a prodrug that through a multistep process, involving hypoxanthine guanine phosphoribosyltransferase mediated coupling of 6MP with phosphoribosyl pyrophosphate, base modification, and further phosphorylation to form 6TGN (Fig. 3). The deoxy form of 6TGN is then incorporated into DNA (DNA-TG) in nucleated cells, which may activate postreplication mismatch repair systems that lead to DNA strand breaks and apoptosis.

A third metabolic pathway is thiomethylation of 6MP and some of its metabolites catalyzed by TPMT, thus reducing DNA-TG formation. Previously, methylated 6MP metabolites were considered largely insignificant for 6MP pharmacodynamics. However, some methylated metabolites, not least methylthioinosine monophosphates (MeMP), are strong inhibitors of purine de novo synthesis. As the purine salvage pathway is low in lymphoblasts that primarily depend on purine de novo synthesis, the reduced levels of endogenous nucleotides and the resulting enhanced DNA-TG incorporation in the presence of MeMP is likely to play a clinical role. Still, the impact of these pharmacodynamic interactions on relapse rates and toxicities remains undetermined, partly as a sufficiently sensitive and reliable assay for routine measurements of DNA-TG in nucleated blood has only recently become available.

After a few weeks of oral 6MP therapy a steady state level in Ery-6TGN level is obtained. Early studies showed Ery-6TGN levels to be associated with both myelotoxicity and remission duration, even though the
6MP metabolite profiles differ widely between red blood cells and neutrophils. However, more recent studies have failed to confirm a significant association between Ery-6TGN and risk of relapse. Ery-6TGN levels reflect adherence to therapy and TPMT activity, but are only weakly, although statistically significantly, related to DNA-TG levels. Furthermore, 6MP dose increments to achieve higher Ery-6TGN levels primarily increase the methylated metabolite levels, which may enhance hepatotoxicity. There is a lack of large, prospective studies that explore

FIGURE 1. Distribution of mean prescribed 6-mercaptopurine (m6MP) doses during maintenance therapy (protocol starting oral dose: 75 mg/m²/d) for 538 patients included in the NOPHO ALL-92 maintenance therapy study. Means are based on a total of >28,000 registered drug doses and calculated by weighting each registered dose according to the time interval to the next measurement. The median m6MP dose for all patients is 59.4 mg/m²/d.

FIGURE 2. Distribution of mean white blood cell count (mWBC) and prescribed mean 6-mercaptopurine (m6MP) doses during maintenance therapy for 538 patients included in the NOPHO ALL-92 maintenance therapy study. Means are based on a total of >28,000 registered drug doses and blood counts and calculated by weighting each registration according to the time interval to the next registration. The median m6MP (59.4 mg/m²/d) and median mWBC (3.3 x 10⁹/L) are significantly correlated (r = 0.20; P < 0.001).
whether monitoring of Ery-6TGN, Ery-MeMP, and DNA-TG adds dose adjustments advantages compared with adjustments by only myelotoxicity and hepatotoxicity.

As dose increments of 6MP increase the methylated metabolites and their associated toxicities far more than Ery-6TGN, several alternative treatment strategies have been efficacious in improving the 6TGN/MeMP ratio, including coadministration of allopurinol and splitting the daily 6MP dose in a morning and an evening dose, but it remains to be determined whether such approaches increase DNA-TG levels, ease 6MP dose adjustments to obtain target WBC/absolute neutrophil counts (ANC) levels, or reduce relapse rates of childhood ALL.

**MTX**

Although MTX disposition and pharmacodynamics have been well mapped in cancer cell lines, far less is known on how to implement such data into maintenance therapy strategies. The folate pathway gene expression profiles vary widely among subsets of ALL, which affects treatment efficacy of MTX. However, current guidelines for MTX dosing do not take into account the diversity of different leukemia subtypes’ sensitivity to MTX.

Bioavailability of low dose oral MTX is generally > 90%, but is significantly reduced at doses > 40 mg/m². Similar to natural folates, MTX is converted into MTX polyglutamates (MTXPG, with 2 to 7 glutamyl residues) by the enzyme folypolyglutamyl transferase, which enhances intracellular retention, inhibition of the target enzymes in purine and pyrimidine de novo synthesis, and treatment efficacy (Fig. 3). The propensity for MTX to undergo polyglutamation is higher for B-cell precursor ALL subtypes (not least the high-hyperdiploid cases) than for T-cell ALL. Accordingly, many groups offer high-dose MTX at doses of 5 g/m²/24 h during consolidation therapy to cure T-cell ALL. MTXPG bind tightly to and inhibit dihydrofolate reductase, the enzyme responsible for reducing folates to their bioactive tetrahydrofolate form. During weekly low-dose oral MTX therapy, MTXPG accumulates in red blood cell precursors in the bone marrow, and MTXPG with longer glutamyl chains are then retained in the erythrocytes (Ery-MTXPG) throughout their life span. Steady-state Ery-MTXPG is achieved after 4 to 8 weeks. A single Nordic study has found Ery-MTXPG levels...
significantly related to remission duration, and this association could not be confirmed in later studies. Potentially due to more intensive use of intravenous MTX in these studies. No study has explored the impact on relapse rates of various Ery-MTX polyglutamate chain lengths. At steady state, Ery-MTX_{PG} is both interindividually and intraindividually related to the dose of oral MTX and may thus be used for monitoring treatment adherence.

PHARMACOGENETICS

Single nucleotide polymorphisms in genes that affect the disposition of anticancer agents influence the outcome of childhood ALL. However, so far only TPMT variants have influenced drug dosing and it is poorly explored which host genome variants that ultimately determine the complex metabolism and efficacy of thiopurines and MTX, how this influences the toxicity profiles across ethnic groups, and how such data should be applied for dose adjustments.

TPMT

The normal substrate for TPMT is not known, and, in the absence of thiopurines, TPMT-deficient individuals are clinically and biochemically normal. In white individuals, the most common variants are *3A, *3B, and *3C all involving G460A and/or A719G and accounting for at least 90% of low-activity alleles among white individuals of North European decent. Approximately 5% to 10% are TPMT heterozygous carrying 1 wild-type and 1 low-activity allele, and 1 in 300 is TPMT deficient and at risk of life-threatening myelosuppression at standard 6MP doses. Although thiopurine dosing according to the TPMT genotype has been implemented by a few ALL study groups, the benefits of this strategy remain uncertain. Compared with TPMT wild-type patients, heterozygous patients experience higher intracellular 6TGN levels, more myelotoxicity, higher cure rates, but probably also a higher risk of second cancers.

Measuring TPMT activity in erythrocytes is an alternative to genotyping and may also identify rare low-activity variants missed by routine allele testing. However, as TPMT activity is inversely related to the erythrocyte age, the TPMT activity will in general be increased during maintenance therapy when the erythrocyte life span is shortened, and be low at diagnosis of ALL due to reduced erythropoiesis, hampering reliable discrimination of heterozygous and wild-type TPMT phenotypes.

Inosine Triphosphate Pyrophosphatase (ITPA)

Low-activity alleles of ITPA, the enzyme that dephosphorylates thionosine triphosphate (Fig. 3), may increase methylated thiopurine metabolite levels, and potentially also the risk of relapse. The frequency of ITPA low-activity alleles show wide interethnic variability being 1% to 2% among Hispanics, but almost 20% in Asian populations, which may influence tolerance to thiopurine therapy.

Other 6MP Metabolizing Genes

Other 6MP metabolizing enzymes, such as xanthine oxidase and hypoxanthine guanine phosphoribosyl transferase (HGPRPT) may vary among individuals, in part determined by genetic polymorphisms, and at least low HGPRPT in B-cell precursor ALL has been associated with an inferior cure rate, although this association was not related to increased in vitro thiopurine resistance.

MTX

Several groups have demonstrated that MTX treatment efficacy is associated with polymorphisms in dihydrofolate reductase, thymidylate synthetase, reduced folate carrier, 5,10-methylenetetrahydrofolate reductase, and methylenetetrahydrofolate dehydrogenase (for reviews on childhood ALL and rheumatoid arthritis, see Davidsen and colleagues). However, the results of these studies are often contradictory with some studies demonstrating improved cure rates for a specific genetic polymorphism, whereas others demonstrate the opposite, many of the studies are small, most only address 1 or a few of the many genetic polymorphisms involved in the disposition of MTX, and in general they address responses to high-dose MTX rather than low-dose MTX maintenance therapy. Furthermore, it is impossible to evaluate whether a specific polymorphism exerts its modifying effect on relapse rate and/or toxicities directly through changed MTX disposition or indirectly by modifying endogenous folate levels. So far no groups have adjusted their MTX treatment strategies based on polymorphisms in the MTX/folate pathway.

TOXICITY AND RELAPSE RATE

Leukopenia

Dose adjustments guided by toxicity assumes that the individual variations in 6MP/MTX pharmacokinetics and/or pharmacodynamics affect leukemic and normal cells in parallel. For maintenance therapy, 6MP/MTX dosage is targeted to a preset degree of myelosuppression, generally a WBC of 1.5 to 3.0 (or 3.5) × 10^9/L, but randomized studies demonstrating benefits hereof are lacking. Most observational studies have shown low WBC and/or ANC during maintenance therapy to be related to red blood cell levels of cytotoxic 6MP/MTX metabolites and/or to a reduced relapse rate. However, ANC correlates so closely with WBC, that it is virtually impossible to determine which of these 2 parameters is superior as guidance for dose adjustment (Fig. 4A). In the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL92 maintenance therapy study, patients with an average ANC < 2.0 × 10^9/L during maintenance therapy had a significantly better relapse-free survival than patients with higher ANC levels (Fig. 4B), and ANC was somewhat more strongly associated with relapse rates than WBC level, although the latter was the dose adjustment target in that protocol. Nevertheless, several factors challenge 6MP/MTX dose adjustments by the leukocyte counts.

First, physicians may be more inclined to decrease 6MP/MTX drug doses in case of toxicity than to escalate...
doses in patients insufficiently myelosuppressed, requiring different strategies for 6MP dose adjustments, if the 6MP starting dose is 50 versus 75 mg/m².

Second, the WBC levels reflect both treatment intensity and the child’s normal WBC level, which varies both between and within age groups, and by ethnicity.

FIGURE 4. A, Mean white blood cell (mWBC) and absolute neutrophil counts (mANC) for 538 patients included in the NOPHO ALL-92 maintenance therapy study. Means are based on a total of >28,000 blood counts and calculated by weighting each measurement according to the time interval to the next measurement. Each dot represents 1 patient. mWBC and mANC are highly correlated ($r_s = 0.77; P < 0.001$). The target range for WBC was 1.5 to $3.5 \times 10^9/L$ in the NOPHO ALL92 protocol from which the data were retrieved. B, Kaplan-Meier relapse risk plots for patients with a mean absolute neutrophil count (mANC) at the end of maintenance therapy above or below $2.0 \times 10^9/L = $median mANC for all patients (upper curve, $N = 248$, relapse risk $23.5\% \pm 2.7\%$; lower curve, $N = 280$, relapse risk $10.9\% \pm 1.9\%; P < 0.001$). Mean absolute neutrophil counts during maintenance therapy are calculated by weighting each measurement according to the time interval to the next measurement.
Thus, patients with lower WBC levels during therapy also have low WBC after cessation of therapy \((r_s = 0.76; P < 0.00001)\), and even more important, the best predictor of the rise in WBC after cessation of therapy is not the WBC level during maintenance therapy, but Ery-6TGN and Ery-MTXPG.\(^\text{102}\) Thus, an average WBC during therapy of \(3.5 \times 10^9/L\) could reflect more intensive treatment than an average WBC of \(3.2 \times 10^9/L\), if the patients’ off-therapy WBC levels were 8.5 and \(4.5 \times 10^9/L\), respectively. In support hereof, the red blood cell 6MP/MTX metabolite levels are overall higher in the former patient, and the rise in WBC following cessation of maintenance therapy is a stronger predictor of relapse than the average WBC level during maintenance therapy, associating a high rise in WBC with a reduced relapse rate after cessation of maintenance therapy.\(^\text{146}\)

Third, often it is not possible to suppress WBC levels to a target range of 1.5 to \(3.0 \times 10^9/L\) by dose intensification without unacceptable extramedullary toxicity, including hepatotoxicity (see below).

Finally, an aggressive approach with higher 6MP doses and higher treatment intensity to achieve low WBC levels may be counteracted by treatment interruptions\(^\text{61}\) or lead to an increased risk of second cancers.\(^\text{51,42}\) Other not yet understood mechanisms such as induction of dormant leukemic stem cells\(^\text{61}\) due to inhibition of purine de novo synthesis could also increase the risk of relapse for the dose-intensified patients.

### Thrombocytopenia

Thrombocyte counts during and after cessation of maintenance therapy are significantly correlated \((r_s = 0.74; P < 0.0001)\),\(^\text{102}\) but thrombocytopenia is rarely a dose-limiting factor during 6MP/MTX maintenance therapy. However, if 6MP is substituted with the alternative thiopurine, thioguanine (6TG), Ery-6TGN levels become 7-fold higher and severe thrombocytopenia becomes 5- to 10-fold more common.\(^\text{147}\) Furthermore, 10% to 15% of 6TG-treated patients develop sinusoidal occlusive disease and/or portal hypertension, which often is accompanied by thrombocytopenia.\(^\text{148-150}\) Patients on 6MP with unexplained thrombocytopenia should be explored for hypersplenism and persistent Parvovirus B19 infection.\(^\text{151}\)

### Hepatotoxicity

6MP and MTX are hepatotoxic and 2-fold elevations or more of serum aminotransferases are frequent,\(^\text{100,146,152-156}\) but usually normalize within a few weeks after discontinuation of maintenance therapy.\(^\text{146,153}\) Hypoglycemic episodes during fasting\(^\text{57-160}\) have been associated with high levels of methylated 6MP metabolites.\(^\text{101}\) It can be counteracted by evening meals with slowly absorbed carbohydrates, by administration of rapidly absorbed carbohydrates (eg, apple juice) in case of symptoms, or by shifting to morning dosage. The latter reduces Ery-MeMP levels but the impact on relapse rate is unknown.\(^\text{161}\) Few patients develop symptoms of hypoglycemia such as severe nausea, itching, or malaise to a degree that requires dose reductions. A moderate rise in bilirubin or reduced levels of coagulation factors is common, but the risk of serious and/or permanent liver damage seems low.\(^\text{162-164}\) Accordingly, most study groups do not recommend dose reductions in case of high aminotransferase levels\(^\text{48}\) unless accompanied by biochemical evidence of severe hepatic dysfunction, that is, bilirubin 3 times above the upper normal limit and/or coagulation factor II-VII-X \(< 0.50\) UI/L. Such patients should be explored for other causes, including hepatotropic vira (eg, B or C virus\(^\text{153,154}\)), veno-occlusive syndrome (VOD), or Gilbert syndrome with reduced glucuronyltransferase activity and elevated unconjugated bilirubin.

In accordance with the high incidence of hepatotoxicity seen with methylmercaptopurine riboside therapy,\(^\text{165,166}\) and the low rate of hepatotoxicity in patients with low TPMT activity,\(^\text{38,89}\) most cases of high aminotransferase levels can be related to high levels of methylated 6MP metabolites,\(^\text{89,167}\) but have also more rarely been proposed to be associated with high Ery-6TGN\(^\text{168}\) or Ery-MTXPG\(^\text{169}\) or to accumulation of 6MP in the liver.\(^\text{169}\)

A small Danish study from the 1980s linked increased aminotransferases levels during maintenance therapy with a reduced relapse rate\(^\text{170}\). This could reflect reduced first-pass effect on oral 6MP with higher systemic 6MP exposure among developing hepatotoxicity, or higher levels of methylthioinosine monophosphate causing both liver toxicity and inhibition of purine de novo synthesis in leukemic cells\(^\text{78,171}\) which could have increased the incorporation of 6TGN into DNA.\(^\text{74,79}\) Alternatively, elevated aminotransferases and reduced relapse risks could merely reflect that the patients were adherent to maintenance therapy. Importantly, patients who continued therapy despite an increase in aminotransferases had a lower relapse rates than patients with treatment interruptions due to hepatotoxicity.\(^\text{37}\)

### 6MP AND MTX INTERACTION

MTX inhibits xanthine oxidase and thereby increases 6MP bioavailability (Fig. 3).\(^\text{172}\) In addition, inhibition of purine de novo synthesis can preserve phosphoribosyl pyrophosphate availability, a necessary substrate for 6TGN formation.\(^\text{171}\) Cellular depletion of reduced (activated) folates may also lower the availability of S-adenosyl methionine, the methyl donor in TPMT-mediated methylation, and thereby reduce 6MP metabolite methylation. For TPMT wild-type patients (but not for patients with TPMT low-activity alleles), Ery-6TGN and Ery-MTXPG correlate significantly during maintenance therapy (Supplemental Fig. 2, Supplemental Digital Content 2, http://links.lww.com/JPHO/A73), and the longer chained MTX polyglutamates seem most important for enhancing Ery-6TGN accumulation.\(^\text{173}\) Because of these synergisms, it is probably better to lower the doses of both 6MP and MTX than to withhold one drug and continue the other in case of dose-limiting toxicity. As the interindividual variation in bioavailability and pharmacokinetics is higher for 6MP than for MTX, above target WBC during maintenance should initially lead to upward dose adjustments in 6MP, followed by dose increments for MTX once the maximum tolerated dose of 6MP has been achieved.

### 6MP VERSUS 6TG FOR MAINTENANCE THERAPY

In 3 randomized studies by the US CCG, the German COALL, and the British UKALL groups that all compared 6MP with 6TG as the maintenance therapy thiopurine, only males below 10 years of age seemed to have reduced relapse rates with 6TG (OR = 0.70; 95% confidence interval, 0.58-0.84), although with no significant difference in overall survival.\(^\text{174}\) The lack of MeMP and the associated inhibition of purine de novo synthesis for patients on 6TG may explain why this thiopurine failed to improve EFS, even though children receiving 6TG had several-fold higher
Ery-6TGN levels. More worrying is that, 10% to 15% of patients on 6TG developed VOD, a few of which were sufficiently severe to require liver transplantation. It is noteworthy that, the German COALL study did not report 6TG-associated VOD, the only major difference from the other 2 studies being the absence of vincristine/glucocorticoid reinductions during maintenance therapy in the German trial. However, the biology behind this association remains unclear.

**PHYSICIAN COMPLIANCE AND PATIENT ADHERENCE TO MAINTENANCE THERAPY**

With the complexity of multiple factors influencing therapy (physician compliance, patient adherence, drug disposition, toxicity), there are many potential layers of failure to optimize maintenance therapy. Toxicity-guided dosing relies heavily on physicians’ willingness to comply with the protocol guidelines, their experience with maintenance therapy, and their ability to explain the pharmacology, the biology of toxicities, and the importance of treatment adherence to patients and parents. Patient adherence will on the contrary reflect the patient’s family’s willingness to accept burdensome toxicities of 6MP and MTX and frequent hospital visits to cure a disease that no longer can be detected. For very young children, not least infants, treatment adherence has been jeopardized by the commercially available 6MP tablets having been developed for adult-sized patients, and not until recently has a liquid formulation of 6MP been marketed (although still not formally tested) in children.

Several groups have reported poor treatment adherence to maintenance therapy in a significant proportion of childhood ALL patients. The reasons for poor medication adherence can be biological, psychological, and social, and they vary across age groups and by ethnicity. Various approaches to address this challenge have been proposed, including routine measurements of Ery-6TGN, Ery-MTX, and Ery-6TGN/MTX levels, but such analyses are only available in a few centers. If 6MP/MTX metabolite measurements are unavailable, nonadherence should be suspected in patients with persistent WBC > 3.0 to 3.5 × 10^9/L despite prescribed 6MP dose increments, and in patients with a TPMT wild-type genotype/pheno type, if dose increments do not lead to a rise in aminotransferases.

The randomized Brazilian ALL99 study indicated that intermittent oral high-dose 6MP with IV MTX 200 mg/m^2/6h not only improved adherence but also gave better pEFS than oral 6MP (50 mg/m^2/d) with IM MTX 25 mg/m^2/wk, although only for boys. However, the extent of patient adherence in the oral 6MP arm is difficult to assess, as 6MP/MTX metabolite measurements were not done, and it is also unclear whether the difference in 6MP and/or MTX dosing in the 2 treatment arms caused the difference in EFS.

**CIRCADIAN SCHEDULE**

The circadian schedule has a strong impact on efficacy and toxicity of a number of anticancer agents. Two maintenance therapy studies from the 1980s and 1990s found that the risk of relapse was several-fold higher for patients who reported taking 6MP and MTX in the morning compared with patients on evening schedule. It was speculated that differences in biological activity between malignant lymphoid cells and normal bone marrow cells determined these chronotherapeutical findings, but whatever the biological mechanism, changing patients from morning to evening schedule seemed a simple procedure to improve outcome, and this has become the general standard. However, a recent large study of 526 children on maintenance therapy with almost 10,000 E-6TGN/MTX measurements, found no association between relapse rates and the cumulative duration of evening dosage for the individual patient, when adjusting for 6MP and MTX doses, WBC levels during maintenance therapy, and Ery-6TGN and Ery-MTX levels.

**FOOD AND MAINTENANCE THERAPY**

Several small studies, although not all, have demonstrated reduced bioavailability for both MTX and 6MP, when the drugs are administered together with food, and for 6MP specifically with milk due to its content of xanthine oxidase. Accordingly, nearly all study groups recommend 6MP and MTX to be taken without concomitant ingestion of food. Still, titrating the dose of MTX and 6MP by toxicity should counterbalance lower bioavailability, and restricting the individual patients’ choices of drug administration could reduce adherence. Only 1 large clinical study has explored the prognostic impact on administering 6MP/MTX with food, and this study demonstrated no significant influence of concomitant food ingestion on relapse rate, this also being the case within subgroups defined by their circadian schedule.

**COADMINISTRATION OF OTHER DRUGS**

It is unproven that alternative or additive components of maintenance therapy such as intravenous 6MP, 6TG, allopurinol, high-dose MTX, vincristine/glucocorticoid, or more intensive reinductions significantly reduce relapse rates with contemporary ALL therapy, although they can add to the burden of myelotoxicity and hepatotoxicity, which may necessitate 6MP and MTX dose reductions. Specifically, vincristine/glucocorticoid pulses during 6MP/MTX have been applied by many groups, but so far most, although not all, randomized studies have failed to demonstrate benefits of such pulses. Folate supplementation has been widely used to counteract MTX-induced toxicity without compromising efficacy in rheumatoid arthritis or post-transplantation. However, folate supplementation should probably be avoided during maintenance therapy, as it has been shown to influence both 6MP metabolism and myelotoxicity. Finally, trimethoprim-sulfamethoxazole given as *Pneumocystis jiroveci* pneumonia prophylaxis interferes with MTX and 6MP pharmacokinetics, and also enhances myelotoxicity leading to lower prescribed 6MP and MTX doses, but in spite hereof does not seem to increase relapse rates and thus seems safe to prescribe to avoid this life-threatening infection.

**RELAPSE DURING MAINTENANCE THERAPY**

Several high-risk ALL subsets such as T-cell ALL, patients with hyperleukocytosis, and patients with t(1;19)[E21-PBX1], *MLL* rearrangements, or hypo-diploidy nearly always relapse during maintenance therapy. In contrast, the majority of other B-cell precursor ALL relapses occurs within 2 to 3 years after cessation of treatment. Relapse during maintenance therapy has been associated with insufficient 6MP treatment intensity as
indicated by low Ery-6TGN levels, or it may simply reflect poor treatment compliance/adherence. Two recent studies demonstrated activating mutations in the NT5C2 gene, which plays a role in nucleotide homeostasis, in approximately 15% to 20% of both B-cell precursor and T-cell ALL patients that relapse during 6MP/MTX maintenance therapy. It is noteworthy that, such mutations are rare among B-cell precursor ALL patients that relapse off therapy, indicating that such patients relapse rapidly when NT5C2 mutations emerge, or that the survival advantage for NT5C2-mutated clones at the cost of normal hematopoietic cells disappears once 6MP therapy is discontinued. In the future, targeted deep sequencing may allow routine screening for emerging clones with mutations that hamper the efficacy of thiopurines or MTX, which would allow modification of maintenance therapy to counteract such resistance mechanisms.

CONCLUSIONS AND FUTURE DIRECTIONS

During the last decades more attention has been paid to dose titration by myelotoxicity, and some groups even monitor 6MP and MTX metabolites to reveal poor treatment adherence. However, until it has been determined that such therapeutic drug monitoring eases dose adjustments, improves cure rates, and/or reduce toxicity, maintenance therapy should be adjusted according to the WBC, and lack of myelotoxicity and hepatotoxicity is regarded as a surrogate marker for nonadherence. Future research should address the applicability of DNA-TG monitoring, extensive host single nucleotide polymorphism profiling, screening methods for resistant leukemic subclones, and alternative thiopurine dosing regimens to improve maintenance therapy for the individual patient.

REFERENCES

1. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med. 1948;238:787–793.
2. Burchenal JH, Murphy ML, Ellison RR, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953;8:965–987.
3. Thomas A, Joe Burchenal and the birth of combination chemotherapy. Br J Haematol. 2006;133:493–503.
4. Frei E III, Caron M, Levin RH, et al. The effectiveness of combinations of antileukemia agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965;26:642–656.
5. Simone JV. The treatment of acute lymphoblastic leukemia. Br J Haematol. 1980;45:1–4.
6. Holland JF, Gildewell O. Chemotherapy of acute lymphocytic leukemia of childhood. Cancer. 1972;30:1480–1487.
7. Lonsdale D, Gahan EA, Fernbach DJ, et al. Interrupted vs. continued maintenance therapy in childhood acute leukemia. Cancer. 1975;36:341–352.
8. Rivera GK, Pinkel D, Simone JV, et al. Treatment of acute lymphoblastic leukemia. 30 years’ experience at St. Jude Children’s Research Hospital. N Engl J Med. 1993;329:1289–1295.
9. Schmiegelow K, Forester E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345–354.
10. Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:255–264.
11. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children’s Oncology Group Report. Leukemia. 2010;24:285–297.
12. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24:309–319.
13. Salzer WL, Devidas M, Carroll WL, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children’s oncology group. Leukemia. 2010;24:355–370.
14. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–284.
15. Schrappe M, Nitzsch J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24:253–254.
16. Sather H, Miller D, Nesbit M, et al. Differences in prognosis for boys and girls with acute lymphoblastic leukemia. Lancet. 1981;1:739–743.
17. Siehm H, Feickert HJ, Schrappe M, et al. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Hamatol Bluttransfus. 1987;30:139–146.
18. Chessells JM, Richards SM, Bailey CC, et al. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol. 1995;89:364–372.
19. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet. 1996;347:1783–1788.
20. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17:818–824.
21. Tzoneva G, Perez-Garcia A, Carpenter Z, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med. 2013;19:368–371.
22. Meyer JA, Wang J, Hogan LE, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45:290–294.
23. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate: Is methotrexate a prodrug? J Clin Invest. 1985;76:907–912.
24. Waters TR, Swann PF. Cytoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry. 1997;36:2501–2506.
25. Kamen BA. Serendipity-methotrexate and 6-mercaptopurine. J Clin Invest. 1996;97:139–146.
26. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukemia. Lancet. 1991;338:1315–1318.
27. Kumagai M, Manabe A, Pui CH, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. Exp Hematol. 1996;24:755–760.
28. Campagna D, Costuan-Smith E, Manabe A, et al. Human B-cell progenitors and bone marrow microenvironment. Hum Cell. 1996;9:317–322.
29. Mudry RE, Fortney JE, York T, et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood. 2000;96:1926–1932.
30. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and...
supports leukemia cell growth. Exp Hematol. 2003;31: 693–701.

31. Perez-Atayde AR, Sallan SE, Tredow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815–821.

32. Keyhani A, Jendiroba DB, Freireich EJ. Angiogenesis and leukemia. Leuk Res. 2001;25:639–645.

33. Schmiegelow K, Heyman M, Kristinson J, et al. Oral methotrexate: 6-mercaptopurine may be superior to a multi-drug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Pediatr Hematol Oncol. 2009;31:385–392.

34. Schmiegelow K, Heyman M, Gustafsson G, et al. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010;24:715–720.

35. Bohnstedt C, Levinsen M, Rosthoj S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukaemia. 2013;27:666–670.

36. Peeters M, Koren G, Jakubovicz D, et al. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther. 1988;43:228–232.

37. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hemato Oncol. 1991;8:301–312.

38. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817–2823.

39. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol. 2012;30:2094–2101.

40. Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165–1174.

41. Schmiegelow K, Al-Modhwaï I, Andersen MK, et al. Methotrexate-6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia—results from the NOPHO ALL-92 study. Blood. 2009;113:6077–6084.

42. Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013;31:2469–2476.

43. Levinsen M, Rotevatn EO, Rosthoj S, et al. Pharmacogenetically based 6-mercaptopurine maintenance with thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:797–802.

44. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomised trials in four consecutive ALL-BFM studies. Hematol Blood Transf. 1990;33:439–450.

45. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508–1516.

46. Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99:1253–1258.

47. Lauten M, Moricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012;97:1048–1056.

48. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia. 2005;19:1145–1152.

49. Chessells JM, Leiper AD, Tiedemann K, et al. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukemia. Arch Dis Child. 1987;62:172–176.

50. Balis FM, Mirro JJ, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6: 1882–1886.

51. Chessells JM, Cox TC, Kendall B, et al. Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation. Arch Dis Child. 1990;65:416–422.

52. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118:243–251.

53. Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphoblastic leukemia. Cancer. 1971;27:247–256.

54. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med. 1983;308:1005–1009.

55. Lafolie P, Hayden S, Bjork O, et al. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Acta Paediatr Scand. 1986;75:97–103.

56. Poplack DG, Balis FM, Zimm S. The pharmacology of orally administered chemotherapy. A reappraisal. Cancer. 1986;58:473–480.

57. Teresi ME, Crom WR, Choi KE, et al. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110:788–792.

58. Koren G, Solh H, Klein J, et al. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics. Med Pediatr Oncol. 1989;17:450–454.

59. Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol. 1995;22:1570–1573.

60. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children’s cancer group and pediatric oncology branch study. Blood. 1998;92:3569–3577.

61. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Pediatr. 2004;144:1332–1339.

62. Pearson AD, Amineddine HA, Yule M, et al. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer. 1991;64:169–173.

63. Schmiegelow K, Forestier E, Kristinson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009;3:557–564.

64. Hayden S, Lafolie P, Bjork O, et al. Methotrexate plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Ther Drug Monit. 1989;11:617–622.

65. Koren G, Ferrazini G, Sulh H, et al. Systemic exposure to 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukemia. Br J Cancer. 2001;85:1132–1137.

66. Balis FM, Mirro JJ, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6: 1882–1886.

67. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetylation, xanthine oxidase, and CYPIA2 activities. Clin Pharmacol Ther. 1992;52:643–658.

68. Zimm S, Collins JM, O’Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of
6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983;34:810–817.

69. Roberts RL, Garry RB, Barclay ML. Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? Pharmacogenomics. 2010;11:1505–1508.

70. Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013;86:539–547.

71. Brackett J, Schafer ES, Leung DH, et al. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer. 2014;61:1114–1117.

72. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–339.

73. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996;273:1109–1111.

74. Hedeland RL, Hvidt K, Nersting J, et al. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2010;66:485–491.

75. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8:24–36.

76. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenomics implementation consortium guidelines for thiopurine methyltransferase genotypes. Clin Pharmacol Ther. 2013;93:324–325.

77. Stet EH, De Abreu RA, Bokkerink JP, et al. Reversal of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside cytotoxicity by amidoxime carboxamide ribonucleoside in Molt F4 human malignant T-lymphoblasts. Biochem Pharmacol. 1993;46:547–550.

78. Bokkerink JP, Stet EH, De Abreu RA, et al. 6-Thioguanine nucleotide metabolism and allopurinol. Clin Pharmacol Ther. 2013;93:324–325.

79. Ebbesen MS, Nersting J, Jacobsen L. DNA incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukaemia—the influence of thiopurine methyltransferase genotypes. J Clin Pharmacol. 2013;53:670–674.

80. Jacobsen JH, Schmiegelow K, Nersting J. Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;881-882:115–118.

81. Belkov VM, Krypetsky EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate polyglutamylase and cytotoxicity. Mol Pharmacol. 1997;52:155–163.

82. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489–503.

83. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115:110–117.

84. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489–503.

85. Schmiegelow K, Schroder H, Pulczynska MK, et al. Main- treatment for childhood acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercapto purine. Cancer Chemother Pharmacol. 1998;42:266–272.

86. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther. 2004;75:274–281.

87. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child. 1997;76:365–366.

88. Erb N, Harms DO, Jank- Schaub G. Pharmacokinetics and metabolites of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42:266–272.

89. Smith MA, Blaker P, Marracki AM, et al. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905–912.

90. Shih DQ, Nguyen M, Zheng L, et al. Partial-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther. 2012;36:449–458.

91. Bell BA, Brockway GN, Shuster JJ, et al. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children’s Oncology Group). Pediatr Blood Cancer. 2004;43:103–109.

92. Sotohoi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008;49:410–426.

93. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008;5:e53.

94. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol. 1997;52:155–163.

95. Schroder H, Fogh K, Herlin T. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes. Cancer Chemother Pharmacol. 1988;21:150–155.

96. Schmiegelow K, Schroder H, Pulezynska MK, et al. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother Pharmacol. 1989;25:65–69.

97. Schroder H. In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes. Dan Med Bull. 1990;37:22–40.

98. Schmiegelow K, Schroder H, Schmiegelow M. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters? Cancer Chemother Pharmacol. 1994;34:209–215.

99. Graham ML, Shuster JJ, Kamen BA, et al. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol. 1992;31:217–222.
104. Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol. 2004;125:421–434.

105. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30:831–849.

106. Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics. 2002;12:191–195.

107. Lu HF, Shih MC, Hsueh SC, et al. Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans. J Clin Pharm Ther. 2003;28:491–496.

108. Lu HF, Shih MC, Chang YS, et al. Molecular analysis of thiopurine S-methyltransferase alleles in Taiwanese. J Clin Pharm Ther. 2006;31:93–98.

109. Toft N, Nygaard U, Gregers J, et al. Genetic analyses of thiopurine methyltransferase polymorphisms in Greenlandic and Danish populations. Acta Paediatr. 2006;95:1665–1667.

110. Kim H, Kang HJ, Kim HJ, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS One. 2012;7:e45558.

111. Lennard L, Lewis IJ, Michelagnoli M, et al. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol. 2000;32:247–255.

112. Andersen JB, Szmulanski C, Weinhilboum RM, et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr. 1998;87:108–111.

113. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus [see comments]. J Natl Cancer Inst. 1999;91:2001–2008.

114. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet. 1990;336:225–229.

115. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34–39.

116. Thomsen JB, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer. 1999;86:1080–1086.

117. Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood. 2009;114:1314–1318.

118. Lennard L, Chew TS, Lilleyman JS. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol. 2001;52:539–546.

119. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85:164–172.

120. Adam-de BT, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012;68:1233–1242.

121. Tanaka Y, Manabe A, Nakadate H, et al. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res. 2012;36:560–564.

122. Wan Rosalina WR, Teh LK, Mohamad N, et al. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther. 2012;37:237–241.

123. Zelnikova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44–49.

124. Adam de BT, Fakhoury M, Medard Y, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol. 2011;71:575–584.

125. Marsh S, King CR, Ahluwalia R, et al. Distribution of ITPA 94C > A and risk of adverse effects among patients with acute lymphoblastic leukemia. Br J Clin Pharmacol. 2004;57:579–581.

126. Lennard L, Hale JP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 1993;36:277–284.

127. Pieters R, Huismans DR, Loonen AH, et al. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukaemia: relation with immunophenotype, transplant resistance and clinical prognosis. Int J Cancer. 1992;51:213–217.

128. Dulucq S, St-Onge G, Gagne V, et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 2008;111:3692–3700.

129. Krajnovic M, Costea I, Primeau M, et al. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J. 2009;5:374–380.

130. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752–4758.

131. Gregers J, Christensen U, Dalhoff K, et al. The association of reduced folate carrier 80G > A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115:4671–4677.

132. Krajnovic M, Lemeux-Blanchard E, Chisson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4:66–72.

133. Krajnovic M, Moghombi A. Pharmacogenetics of methotrexate. Pharmaco genomics. 2004;5:819–834.

134. Kager L, Evans WE. Pharmacogenomics of acute lymphoblastic leukemia. Curr Opin Hematol. 2006;13:260–263.

135. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics. 2008;9:439–451.

136. Schmiegelow K. Maintenance chemotherapy of acute lymphoblastic leukaemia in children. Dan Med Bull. 1998;45:510–532.

137. van Eys J, Berry D, Crist W, et al. Treatment intensity and outcome for children with acute lymphocytic leukaemia of standard risk. A Pediatric Oncology Group Study. Cancer. 1989;63:1466–1471.

138. Lennard L, Rees CA, Lilleyman JS, et al. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:359–363.

139. Schmiegelow K, Pulcynska MK, Scip M. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate. Pediatr Hematol Oncol. 1988;5:259–267.

140. Dolan G, Lilleyman JS, Richards SM. Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council. Br J Dis Child. 1989;64:1231–1234.

141. Gobrecht O, Gobel U, Graubner U, et al. Effect of dose intensity and therapy-induced leukocytopenia in intensive therapy on the prognosis of acute lymphatic leukemia in childhood. Results in 213 patients of the COALL-85 study. Acta Paediatr. 1997;86:230–235.

142. Hayden S, Bjork O, Nilsson B. Relapse factors during maintenance therapy of acute lymphoblastic leukemia in children. Pediatr Hematol Oncol. 1992;9:21–27.
143. Lucas K, Gula MJ, Blatt J. Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Pediatr Hematol Oncol. 1992;9:91-97.

144. Chessel D, Harrison G, Lilleyman JS, et al. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol. 1997;98: 945-951.

145. Schmiegelow K, Pulczynska M. White-cell counts in childhood acute lymphoblastic leukaemia. Eur J Haematol. 1990; 44:62-74.

146. Schmiegelow K, Iversen M. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukaemia. Pediatr Hematol Oncol. 1996;13:433-441.

147. Harms DO, Gobel U, Spaar HJ, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood acute leukaemia. Results of the randomized trial COALL-92. Blood. 2003;102:2736-2740.

148. Satti MB, Weinbren K, Gordon-Smith EC, 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol. 1982;35:1086-1091.

149. Broxson EH, Dole M, Wong R, et al. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukaemia treated with oral 6-mercaptopurine during maintenance therapy. Pediatr Blood Cancer. 2005;44: 226-231.

150. Escherich G, Horstmann MA, Zimmermann M, et al. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia. 2010;24:298-308.

151. Heegaard ED, Kerdnap GB, Carlsen NT, et al. [Thrombocytopenia caused by Parvovirus B19 infection in a child with acute lymphocytic leukaemia]. Ugeskr Laeger. 1999;161: 6501-6502.

152. Topley JM, Benson J, Squier MV, et al. Hepatotoxicity in the treatment of acute lymphoblastic leukaemia. Med Pediatr Oncol. 1979;7:393–399.

153. Bessho F, Kinumaki H, Yokota S, et al. Liver function studies in children with acute lymphocytic leukaemia after cessation of therapy. Med Pediatr Oncol. 1994;23:111-115.

154. Farrow AC, Buchanan GR, Zwiener RJ, et al. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukaemia. J Clin Oncol. 1997;15:1560–1566.

155. Schmiegelow K, Breton-Meyer U. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukaemia. Leukemia. 2001;15:74-79.

156. Halonen P, Mattila J, Makiperna A, et al. Erythrocyte metabolites in children with acute lymphoblastic leukaemia. Br J Cancer. 1997;73:110-117.

157. Halonen P, Mattila J, Suominen P, et al. Liver histology after treatment of childhood acute lymphoblastic leukaemia and metastatic cancer. Acta Pediatr. 1998;52:315–320.

158. Trelinska J, Fendler W, Szadkowska A, et al. Hypoglycemia and glycemic variability among children with acute lymphoblastic leukaemia during maintenance therapy. Leuk Lymphoma. 2011;52:1704–1710.

159. El-Bitar MK, Muwakkit SA, Dabbagh O. Severe hypoglycemia in children with standard risk acute lymphoblastic leukaemia: a collaborative Children’s Oncology Group/ National Cancer Institute pilot trial (CCG-1942). Pediatr Blood Cancer. 2007;49:250–255.

160. Dervieux T, Hancock M, Evans W, et al. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukaemia with mercaptopurine. Leukemia. 2002;16: 209–212.

161. Bodey GP, Brodovsky HS, Isassi AA, et al. Studies of 6-mercaptopurine (NSC-755) and 6-methylmercapto purine riboside (NSC-40774) in patients with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92: 37–42.

162. Bodey GP, Brodovsky HS, Isassi AA, et al. Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercapto purine riboside in patients with acute lymphoblastic leukaemia. Acta Paediatr. 1996;52:315–320.

163. Lucas K, Gula MJ, Blatt J. Relapse in acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1992;9:91-97.

164. Halonen P, Mattila J, Ruuska T, et al. Liver histology after treatment of childhood acute lymphoblastic leukaemia: microvesicular fatty change and siderosis are the main findings. Med Pediatr Oncol. 2003;40:148–154.

165. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92: 37–42.

166. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.

167. Halonen P, Mattila J, Ruuska T, et al. Liver histology after treatment of childhood acute lymphoblastic leukaemia: microvesicular fatty change and siderosis are the main findings. Med Pediatr Oncol. 2003;40:148–154.

168. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.

169. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.

170. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.

171. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.

172. Halonen P, Sala MK, Schmiegelow K, et al. Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia. Acta Paediatr. 2003;92:37-42.
179. Breitkreuz J, Buckman J, Fischer R, et al. Comparative in vitro studies on different 6-mercaptopurine formulations for use in children. *Paediatr Perinat Drug Ther*. 2007;3:31–39.

180. Mulla H, Leary A, White P, et al. A step toward more accurate dosing for mercaptopurine in childhood acute lymphoblastic leukemia. *J Clin Pharmacol*. 2012;52:161–163.

181. Lennard L, Welch J, Lillyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance? *Br J Cancer*. 1995;72:1004–1006.

182. Lau RC, Matsui D, Greenberg M, et al. Electronic measurement of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia. *Med Pediatr Oncol*. 1998;30:85–90.

183. Pritchard MT, Butow PN, Stevens MM, et al. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. *J Pediatr Hematol Oncol*. 2006;28:816–823.

184. Hanghe S, Boisen KA. Self-reported barriers to medication adherence among chronically ill adolescents: a systematic review. *J Adolesc Health*. 2014;54:121–138.

185. Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Leukemia Cooperative Group—protocol ALL-99. *J Clin Oncol*. 2010;28:1911–1918.

186. Hrushesky WJ, Bjarnason GA. Circadian cancer therapy. *J Clin Oncol*. 1993;11:1403–1417.

187. Rivard GE, Infante-Rivard C, Hoyoux C, et al. Maintenance medication adherence in pediatric acute lymphoblastic leukemia: a review. *J Pediatr Hematol Oncol*. 2006;28:816–823.

188. Schmiegelow K, Glomstein A, Kristinsson J, et al. Impact of intermittent use of 6-mercaptopurine and methotrexate in maintenance of compliance with mercaptopurine in pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL); report of the EORTC randomized phase 3 trial 58951. *Blood*. 2010;116:36–44.

189. Ramot B, Brok-Simoni F, Chweidan E, et al. Food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. *Pediatr Hematol Oncol*. 1997;19:102–109.

190. Riccardi R, Balis FM, Ferrara P, et al. Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. *Pediatr Hematol Oncol*. 1986;3:319–324.

191. Bonnichsen P, Nielsen PH, Christiansson I, et al. The effect of food on the absorption of methotrexate in healthy volunteers. *Arthritis Rheum*. 1992;35:761–764.

192. Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. *J Rheumatol*. 1995;22:630–632.

193. de Lemos ML, Hamata L, Jennings S, et al. Interaction between mercaptopurine and milk. *J Oncol Pharm Pract*. 2007;13:237–240.

194. Pinkel D. Intravenous mercaptopurine: life begins at 40. *J Clin Oncol*. 1993;11:1826–1831.

195. Boatner BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. *Blood*. 2001;101:3809–3817.

196. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. *Lancet*. 2007;369:123–131.

197. Eden T, Pieters R, Richards S. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia—an individual patient data meta-analysis involving 5659 children. *Br J Haematol*. 2010;149:722–733.

198. Adam de Beaumais T, Dervieux T, Fakhoury M, et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. *Cancer Chemother Pharmacol*. 2010;66:653–658.

199. Nygaard U, Schmiegelow K. Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukaemia. *Leukemia*. 2003;17:1344–1348.

200. van Kooten Niekker PB, Schmiegelow K, Schroeder H. Influence of methylene blue coadministration on antagonisms and coadministration of antimetabolites on toxicity after high dose methotrexate. *Eur J Haematol*. 2008;81:391–398.

201. De MB, Iacu S, Bertrand Y, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL); report of the EORTC randomized phase 3 trial 58951. *Blood*. 2010;116:36–44.

202. Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. *J Clin Oncol*. 1991;9:1012–1021.

203. Felice MS, Rossi JG, Gallego MS, et al. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy. *Pediatr Blood Cancer*. 2011;57:45–55.

204. Shea B, Swinden MV, Tanjong GE, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *Cochrane Database Syst Rev*. 2013;5:CD002027.

205. Robien K, Schubert MM, Yasui Y, et al. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation. *Bone Marrow Transplant*. 2006;37:687–692.

206. Lennard L, Lilleyman JS, Maddocks JL. The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukaemia. *Br J Cancer*. 1986;53:115–119.

207. Schroeder H, Clausen N, Ostergaard E, et al. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. *Pediatr Hematol Oncol*. 1986;3:241–247.

208. Poulsen A, Demeny AK, Bang PC, et al. Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. *Med Pediatr Oncol*. 2001;37:20–23.

209. Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. *J Pediatr*. 1990;117:823–828.

210. Rees CA, Lennard L, Lilleyman JS, et al. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia. *Cancer Chemother Pharmacol*. 1984;12:87–89.
215. Levinsen M, Shabanah D, Bohnstedt C, et al. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. *Eur J Haematol*. 2012;88:78–86.

216. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood*. 2011;118:2077–2084.

217. Vaitkeviciene G, Heyman M, Jonsson OG, et al. Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count. *Leukemia*. 2013;27:2259–2262.

218. Rubnitz JE, Camitta BM, Mahmoud H, et al. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. *J Clin Oncol*. 1999;17:191–196.

219. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. *Blood*. 2007;110:1112–1115.

220. Forestier E, Johansson B, Gustafsson G, et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. *Br J Haematol*. 2000;110:147–153.

221. Schmiegelow K, Pulczynska MK. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: should dosage be guided by white blood cell counts? *Am J Pediatr Hematol Oncol*. 1990;12:462–467.